2007
Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2007, 120: 1146-1152. PMID: 17904628, PMCID: PMC3476046, DOI: 10.1016/j.jaci.2007.07.055.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsCost-effectiveness ratioSevere asthmaEvent ratesSevere allergic asthmaQuality-adjusted monthsAllergic asthmaMost patientsAlternative medicationsHigher acquisition costUS FoodAsthmaDrug AdministrationLife yearsPatientsIncremental costDisease managementOmalizumabCost-effective optionTreatmentAcquisition costsEconomic outcomesCorticosteroidsMedicationsClinicians
2005
An Asthma Policy Model
Paltiel A, Kuntz K, Weiss S, Fuhlbrigge A. An Asthma Policy Model. International Series In Operations Research & Management Science 2005, 70: 659-693. DOI: 10.1007/1-4020-8066-2_26.Peer-Reviewed Original Research
2003
PRPI 9: BONE MINERAL DENSITY LOSS AFFECTS ESTIMATES OF THE COSTEFFECTIVENESS OF INHALED STEROIDS IN ASTHMA
Paltiel A, Fuhlbrigge A, Kitch B, Rashti R, Weiss, Lee S, Kuntz K. PRPI 9: BONE MINERAL DENSITY LOSS AFFECTS ESTIMATES OF THE COSTEFFECTIVENESS OF INHALED STEROIDS IN ASTHMA. Value In Health 2003, 6: 369. DOI: 10.1016/s1098-3015(10)64272-6.Peer-Reviewed Original Research
2002
A novel approach to defining the relationship between lung function and symptom status in asthma
Kuntz KM, Kitch BT, Fuhlbrigge AL, Paltiel AD, Weiss ST. A novel approach to defining the relationship between lung function and symptom status in asthma. Journal Of Clinical Epidemiology 2002, 55: 11-18. PMID: 11781117, DOI: 10.1016/s0895-4356(01)00412-7.Peer-Reviewed Original ResearchConceptsAsthma-related symptomsLung functionMean lung functionAverage baseline valuePopulation-wide basisExpiratory volumeSymptom daysSymptom scoresNighttime awakeningsSymptom statusClinical trialsMean changeBaseline valuesLinear regression analysisSymptomsRegression analysisNegative associationOverall improvementAssociationAsthmaConsistent relationshipTrials
2001
Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model
Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. Journal Of Allergy And Clinical Immunology 2001, 108: 39-in4. PMID: 11447380, DOI: 10.1067/mai.2001.116289.Peer-Reviewed Original ResearchConceptsSymptom-free daysCorticosteroid therapyAcute exacerbationModerate asthmaHealth-related qualityPopulation of patientsCost-effectiveness findingsHealth care costsCost-effectiveness analysisTotal health costsAdult asthmaObservational cohortRandomized trialsPatient preferencesPatient surveyClinical impactCorticosteroidsSide effectsCare costsDrug efficacyNatural historyAsthmaIncremental costTherapyMild